Skip to main content
Premium Trial:

Request an Annual Quote

Chad Mirkin, Edward Scolnick, Peter Linsley

Premium
Arrowhead Research said this week that it has appointed Chad Mirkin to its newly established board of scientific strategy.
 
Mirkin is the director of the International Institute for Nanotechnology, and a professor of chemistry, medicine, and materials science and engineering at Northwestern University. He holds a BS from Dickinson College and a PhD in chemistry from Pennsylvania State University.
 

 
Alnylam Pharmaceuticals has appointed Edward Scolnick to its board of directors and scientific advisory board.
 
Scolnick is the director of the Psychiatry Initiative at the Broad Institute. Previously, he held a number of positions at Merck Research Laboratories including president. Before that, he worked for the National Cancer Institute and the National Heart Institute.
 
He holds an AB and MD from Harvard Medical School.
 

 
Regulus Therapeutics, a microRNA therapeutics joint venture between Alnylam Pharmaceuticals and Isis Pharmaceuticals, has named Peter Linsley as its CSO.
 
Linsley was previously executive director of cancer biology at Merck Research Laboratories. Before that, he held a number of roles at Rosetta Inpharmatics before it was acquired by Merck.
 
He holds a BS from Auburn University and a PhD from the Molecular Biology Institute of the University of California, Los Angeles.

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.